|Bid||96.91 x 100|
|Ask||97.95 x 100|
|Day's Range||102.35 - 104.79|
|52 Week Range||90.10 - 112.97|
|PE Ratio (TTM)||19.01|
|Earnings Date||Apr 18, 2018 - Apr 23, 2018|
|Forward Dividend & Yield||2.00 (1.91%)|
|1y Target Est||108.81|
This could indicate that investors who seek to profit from falling equity prices are not currently targeting DGX. DGX credit default swap spreads are within the middle of their range for the last three years.
The Zacks Analyst Blog Highlights: CA, Quest Diagnostics, Pfizer, United Parcel and U.S. Bancorp
The healthcare sector has a higher prevalence of companies with sustainable competitive advantages compared to other sectors which implies it may continue generating robust excess returns. When the economy isRead More...
Quest Diagnostics (DGX) grows on infectious disease testing, prescription drug monitoring and wellness business. New collaborations with hospitals and integrated delivery networks are other positives.
Rise in bond yields increased the opportunity cost of investing in other asset classes such as equities, thus, making them less attractive.
Secaucus, NJ, Feb. 01, 2018-- Quest Diagnostics, the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of Mobile Medical ...
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
The Secaucus, New Jersey-based company said it had profit of $1.82 per share. Earnings, adjusted for one-time gains and costs, came to $1.38 per share. The results surpassed Wall Street expectations. The ...
NEW YORK, NY / ACCESSWIRE / February 1, 2018 / Quest Diagnostics Incorporated (NYSE: DGX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 1, 2018 at 8:30 AM ...
A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Quest Diagnostics Incorporated (NYSE:DGX) has returned toRead More...
- Fourth quarter revenues of $1.94 billion , up 4.1% versus 2016 - Fourth quarter diluted EPS of $1.82 on a reported basis, up 67.0% from 2016 primarily due to a tax benefit recorded as a result of the ...
Chairman, President and CEO of Quest Diagnostics Inc (NYSE:DGX) Stephen H Rusckowski sold 106,840 shares of DGX on 01/29/2018 at an average price of $107 a share.
Secaucus, NJ, Jan. 30, 2018-- Quest Diagnostics, the world’ s leading provider of diagnostic information services, announced today that its ChartMaxx ® enterprise content management solution ranked number ...
Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.
Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.
SECAUCUS, N.J., Jan. 23, 2018 /PRNewswire/ -- Quest Diagnostics (DGX), the world's leading provider of diagnostic information services, today announced it has formed a definitive agreement to acquire Mobile Medical Examination Service (MedXM), a leading national provider of home-based health risk assessments and related services. Extended care services help health plans and providers better assess their populations and close gaps in care, with a focus on connecting with patients in homes, retail stores and other convenient settings. "Closing critical gaps in patient care, and doing so when and where it's convenient for consumers, is important to health plans and essential to empowering better health," said Steve Rusckowski, Chairman, President and CEO, Quest Diagnostics.